 | | Vol. 12.42 – 26 October, 2021 |
| |
|
|
| Scientists designed a ferritin-based As nanomedicine, As@Fn, that bound to leukemia cells with very high affinity, and efficiently delivered cytotoxic AsIII into a large diversity of leukemia cell lines and patient cells.
[Nature Nanotechnology] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers used single-cell transcriptome and chromatin accessibility profiling and reported that distinct transcriptional states co-existed in individual cancer cells and that differential transcriptional regulon usage and enhanced rewiring underlied these alternative transcriptional states.
[Nature Cell Biology] |
|
|
|
| The authors performed whole-genome sequencing of 150 adult T cell leukemia/lymphoma (ATL) cases and revealed the overarching landscape of genetic alterations in ATL.
[Blood] |
|
|
|
| Investigators advanced the understanding of biological characteristics, improved disease stratification, and identified molecular targets of adult B cell acute lymphoblastic leukemia (B-ALL). They highlighted the age-dependent distribution of subtypes in prognostic differences between adult and pediatric B-ALL.
[Blood] |
|
|
|
| Scientists synthesized gold nanorods (GNRs) of different aspect ratios and used a binary surfactant mixture of hexadecyltrimethylammonium bromide and sodium oleate. Surface functionalization was followed by chitosan and GNRa-CSP12 was selectively taken up by leukemia cells via targeted endocytosis.
[Journal of the American Chemical Society] |
|
|
|
| The authors showed that miR-126 enhanced MYC activity through the SPRED1/PLK2-ERK-MYC axis. Genetic deletion of miR-126 significantly reduced acute myeloid leukemia rate and extended survival in CBFB-MYH11 knock-in mice.
[Nature Communications] |
|
|
|
| Researchers demonstrated that the frequent germline pathogenic DDX41 variants characterized a clinically distinct acute myeloid leukemia (AML) entity. Features characteristic of DDX41-mutated AML included male predominance, indolent course, and frequent somatic DDX41 variants.
[Leukemia] |
|
|
|
| Investigators demonstrated that addition of a commonly used anti-epileptic, valproic acid, to low dose bezafibrate and medroxyprogesterone acetate (BaP) enhanced the killing of acute myeloid leukemia (AML) cell lines/primary AML cells to levels similar to high dose BaP.
[British Journal of Cancer] |
| |
|
|
| Scientists investigated whether specific fibrin clot properties measured after three to four months of anticoagulation characterized venous thromboembolism patients with subsequent arterial thromboembolism.
[Scientific Reports] |
|
|
|
| Researchers examined the pharmacokinetics and pharmacodynamics of alemtuzumab in adults with sickle cell disease who received a matched related donor HSC transplant and determined if the clearance of alemtuzumab affected transplant outcomes.
[Pharmacotherapy] |
|
|
|
| The authors evaluated the effect of reducing the melphalan dose and retrospectively compared transplant outcomes in 156 patients who received fludarabine with intravenous busulfan or fludarabine with intermediate-dose melphalan at the center.
[International Journal of Hematology] |
|
|
|
|
| Investigators review the most recent studies that provide experimental evidence showing how specific p21-activated kinases regulate the properties of leukemic stem cells and drug-resistant cells to initiate and maintain hematological malignancies.
[Leukemia] |
|
|
|
| Scientists review CD200 expression and its role in the immune evasion of non-B cell hematopoietic neoplasms and conclude that CD200 appears to be involved in the immune evasion of malignant cells, which could affect the survival of patients.
[Critical Reviews in Oncology Hematology] |
|
|
|
| The authors summarize what is currently known about extramedullary hematopoietic stem and progenitor cells and extramedullary hematopoiesis in mice and humans.
[Experimental Hematology] |
|
|
|
|
| Humanigen, Inc. announced the first patient was dosed with lenzilumab in the Precision Approach to Chronic Myelomonocytic Leukemia clinical trial.
[Humanigen, Inc.] |
|
|
|
| ALX Oncology Holdings, Inc. announced the first patient has been dosed in the Phase I/II ASPEN-05 study evaluating the combination of evorpacept with venetoclax and azacitidine for the treatment of patients with acute myeloid leukemia.
[ALX Oncology Holdings, Inc.] |
|
|
|
|
| December 1 – 10, 2021
Virtual |
|
|
|
|
|
| | Icahn School of Medicine at Mount Sinai – New York, New York, United States |
|
|
|
| | Boston Children’s Hospital – Boston, Massachusetts, United States |
|
|
|
| | University of Manitoba – Winnipeg, Manitoba, Canada |
|
|
|
| | The University of Kansas – Kansas City, Kansas, United States |
|
|
|
| | The University of New Mexico – Albuquerque, New Mexico, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
